These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 24835528)

  • 1. Remission of disseminated cancer after systemic oncolytic virotherapy.
    Russell SJ; Federspiel MJ; Peng KW; Tong C; Dingli D; Morice WG; Lowe V; O'Connor MK; Kyle RA; Leung N; Buadi FK; Rajkumar SV; Gertz MA; Lacy MQ; Dispenzieri A
    Mayo Clin Proc; 2014 Jul; 89(7):926-33. PubMed ID: 24835528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma.
    Dispenzieri A; Tong C; LaPlant B; Lacy MQ; Laumann K; Dingli D; Zhou Y; Federspiel MJ; Gertz MA; Hayman S; Buadi F; O'Connor M; Lowe VJ; Peng KW; Russell SJ
    Leukemia; 2017 Dec; 31(12):2791-2798. PubMed ID: 28439108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma.
    Peng KW; Dogan A; Vrana J; Liu C; Ong HT; Kumar S; Dispenzieri A; Dietz AB; Russell SJ
    Am J Hematol; 2009 Jul; 84(7):401-7. PubMed ID: 19507209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma.
    Packiriswamy N; Upreti D; Zhou Y; Khan R; Miller A; Diaz RM; Rooney CM; Dispenzieri A; Peng KW; Russell SJ
    Leukemia; 2020 Dec; 34(12):3310-3322. PubMed ID: 32327728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide.
    Myers RM; Greiner SM; Harvey ME; Griesmann G; Kuffel MJ; Buhrow SA; Reid JM; Federspiel M; Ames MM; Dingli D; Schweikart K; Welch A; Dispenzieri A; Peng KW; Russell SJ
    Clin Pharmacol Ther; 2007 Dec; 82(6):700-10. PubMed ID: 17971816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.
    Reddi HV; Madde P; McDonough SJ; Trujillo MA; Morris JC; Myers RM; Peng KW; Russell SJ; McIver B; Eberhardt NL
    Cancer Gene Ther; 2012 Sep; 19(9):659-65. PubMed ID: 22790962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.
    Hasegawa K; Pham L; O'Connor MK; Federspiel MJ; Russell SJ; Peng KW
    Clin Cancer Res; 2006 Mar; 12(6):1868-75. PubMed ID: 16551872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers.
    Liu C; Russell SJ; Peng KW
    Mol Ther; 2010 Jun; 18(6):1155-64. PubMed ID: 20234340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview.
    Msaouel P; Dispenzieri A; Galanis E
    Curr Opin Mol Ther; 2009 Feb; 11(1):43-53. PubMed ID: 19169959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic measles virus encoding thyroidal sodium iodide symporter for squamous cell cancer of the head and neck radiovirotherapy.
    Li H; Peng KW; Russell SJ
    Hum Gene Ther; 2012 Mar; 23(3):295-301. PubMed ID: 22235810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies.
    Ong HT; Hasegawa K; Dietz AB; Russell SJ; Peng KW
    Gene Ther; 2007 Feb; 14(4):324-33. PubMed ID: 17051248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taming measles virus to create an effective cancer therapeutic.
    Bell JC
    Mayo Clin Proc; 2014 Jul; 89(7):863-5. PubMed ID: 24835529
    [No Abstract]   [Full Text] [Related]  

  • 13. Measles to the Rescue: A Review of Oncolytic Measles Virus.
    Aref S; Bailey K; Fielding A
    Viruses; 2016 Oct; 8(10):. PubMed ID: 27782084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.
    Galanis E; Atherton PJ; Maurer MJ; Knutson KL; Dowdy SC; Cliby WA; Haluska P; Long HJ; Oberg A; Aderca I; Block MS; Bakkum-Gamez J; Federspiel MJ; Russell SJ; Kalli KR; Keeney G; Peng KW; Hartmann LC
    Cancer Res; 2015 Jan; 75(1):22-30. PubMed ID: 25398436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of medulloblastoma using an oncolytic measles virus encoding the thyroidal sodium iodide symporter shows enhanced efficacy with radioiodine.
    Hutzen B; Pierson CR; Russell SJ; Galanis E; Raffel C; Studebaker AW
    BMC Cancer; 2012 Nov; 12():508. PubMed ID: 23134812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter.
    Dingli D; Peng KW; Harvey ME; Greipp PR; O'Connor MK; Cattaneo R; Morris JC; Russell SJ
    Blood; 2004 Mar; 103(5):1641-6. PubMed ID: 14604966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective radiovirotherapy for malignant gliomas by using oncolytic measles virus strains encoding the sodium iodide symporter (MV-NIS).
    Opyrchal M; Allen C; Iankov I; Aderca I; Schroeder M; Sarkaria J; Galanis E
    Hum Gene Ther; 2012 Apr; 23(4):419-27. PubMed ID: 22185260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Converting tumor-specific markers into reporters of oncolytic virus infection.
    Iankov ID; Hillestad ML; Dietz AB; Russell SJ; Galanis E
    Mol Ther; 2009 Aug; 17(8):1395-403. PubMed ID: 19471250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth.
    Munguia A; Ota T; Miest T; Russell SJ
    Gene Ther; 2008 May; 15(10):797-806. PubMed ID: 18356812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic virotherapy for multiple myeloma.
    Stief AE; McCart JA
    Expert Opin Biol Ther; 2008 Apr; 8(4):463-73. PubMed ID: 18352850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.